Target product profile for a diagnostic test to confirm visceral leishmaniasis
Author: World Health Organization
Publisher: World Health Organization
Published: 2024-09-04
Total Pages: 18
ISBN-13: 9240098712
DOWNLOAD EBOOKRead and Download eBook Full
Author: World Health Organization
Publisher: World Health Organization
Published: 2024-09-04
Total Pages: 18
ISBN-13: 9240098712
DOWNLOAD EBOOKAuthor: World Health Organization
Publisher: World Health Organization
Published: 2024-06-26
Total Pages: 16
ISBN-13: 9240091815
DOWNLOAD EBOOKThe purpose of the target product profile for a diagnostic test for confirmation of a cure for visceral leishmaniasis is to communicate the minimum and ideal characteristics desired to meet the need for an in vitro, laboratory-based test for confirming or rejecting a successful cure post-treatment.
Author:
Publisher: World Health Organization
Published: 2022-03-31
Total Pages: 14
ISBN-13: 9240045228
DOWNLOAD EBOOKAuthor: John Gyapong
Publisher: Springer
Published: 2016-01-13
Total Pages: 421
ISBN-13: 3319254715
DOWNLOAD EBOOKThis book provides an overview on the major neglected tropical diseases (NTDs) occurring in Sub-Saharan Africa, such as Leishmaniasis, Buruli Ulcer and Schistosomiasis. In well-structured chapters epidemiology and biology of these parasitic diseases will be discussed in detail. Further, diagnostics and therapeutic approaches as well as prevention strategies will be reviewed. The book will be of interest to basic researchers and clinicians engaged in infectious disease, tropical medicine, and parasitology, and a must-have for scientists specialized in the characteristics of the Sub-Saharan region.
Author: T.K. Jha
Publisher: Springer Science & Business Media
Published: 2011-01-05
Total Pages: 149
ISBN-13: 9400702779
DOWNLOAD EBOOKTherapeutic regimens for visceral leishmaniasis (also Kala-azar, Dum-dum fever or black fever), caused by parasitic protozoa of the Leishmania genus, evolve at a pace never seen before. Spread by tiny and abundant sand flies, the parasite infects internal organs and bone marrow and if left untreated will almost always result in the death of the host. In developing countries successful diagnosis and treatment are complicated by asymptomatic cases, undernutrition and Kala-azar/HIV co-infections. This book brings together world-renown experts writing state-of-arts review on the progress in diagnosis and treatment of visceral leishmaniasis, ultimately leading to the complete elimination of this fatal disease from South Asia. The chapters provide valuable information for disease control as well as therapy and the diagnostic improvements necessary for early treatment, subclinical detection and drug-resistant cases. The presented methods allow for points-of-care testing in the endemic area, enabling rapid detection in resource-poor settings with easy handling and low costs. This book provides essential information for scientists, medical practitioners and policy makers involved in the diagnosis, treatment and elimination of Kala-azar.
Author: World Health Organization
Publisher:
Published: 2012
Total Pages: 0
ISBN-13: 9789240689992
DOWNLOAD EBOOKThe Disease Reference Group on Chagas Disease Human AfricanTrypanosomiasis and Leishmaniasis (DRG3) was part of an independent thinktankof international experts established by the Special Programme for Researchand Training in Tropical Diseases (TDR) to identify key research prioritiesthrough systematic review of research evidence and input from stakeholders. These three distinct insect-borne diseases while caused by related kinetoplastidprotozoan pathogens have dissimilar geographical distributions a reflection oftheir different insect vectors and range of vector contact with humans. Thedisease.
Author: World Health Organization
Publisher: World Health Organization
Published: 2019-05-16
Total Pages: 73
ISBN-13: 9241210265
DOWNLOAD EBOOKThe objective of the list is to help countries develop or update their national essential diagnostics lists, raise awareness and political will, guide procurement and regulation policies and improve access to the most important in vitro diagnostics that all countries need to make available to their populations, particularly in low-resourced countries. It will also contribute towards health systems strengthening and realizing universal health coverage.
Author: Divya Vohora
Publisher: Academic Press
Published: 2017-11-14
Total Pages: 527
ISBN-13: 0128020989
DOWNLOAD EBOOKPharmaceutical Medicine and Translational Clinical Research covers clinical testing of medicines and the translation of pharmaceutical drug research into new medicines, also focusing on the need to understand the safety profile of medicine and the benefit-risk balance. Pharmacoeconomics and the social impact of healthcare on patients and public health are also featured. It is written in a clear and straightforward manner to enable rapid review and assimilation of complex information and contains reader-friendly features.As a greater understanding of these aspects is critical for students in the areas of pharmaceutical medicine, clinical research, pharmacology and pharmacy, as well as professionals working in the pharmaceutical industry, this book is an ideal resource. - Includes detailed coverage of current trends and key topics in pharmaceutical medicine, including biosimilars, biobetters, super generics, and - Provides a comprehensive look at current and important aspects of the science and regulation of drug and biologics discovery
Author: World Health Organization
Publisher: World Health Organization
Published: 2015-08-05
Total Pages: 211
ISBN-13: 9241564865
DOWNLOAD EBOOK"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.
Author: Paulina Balbas
Publisher: Springer Science & Business Media
Published: 2008-02-04
Total Pages: 505
ISBN-13: 1592597742
DOWNLOAD EBOOKSince newly created beings are often perceived as either wholly good or bad, the genetic alteration of living cells impacts directly on a symbolic meaning deeply imbedded in every culture. During the earlier years of gene expression research, te- nological applications were confined mainly to academic and industrial laboratories, and were perceived as highly beneficial since molecules that were previously unable to be separated or synthesized became accessible as therapeutic agents. Such were the success stories of hormones, antibodies, and vaccines produced in the bacterium Escherichia coli. Originally this bacterium gained fame among humans for being an unwanted host in the intestine, or worse yet, for being occasionally dangerous and pathogenic. H- ever, it was easily identified in contaminated waters during the 19th century, thus becoming a clear indicator of water pollution by human feces. Tamed, cultivated, and easily maintained in laboratories, its fast growth rate and metabolic capacity to adjust to changing environments fascinated the minds of scientists who studied and modeled such complex phenomena as growth, evolution, genetic exchange, infection, survival, adaptation, and further on—gene expression. Although at the lower end of the complexity scale, this microbe became a very successful model system and a key player in the fantastic revolution kindled by the birth of recombinant DNA technology.